01—Abstract
Summary
Summary of the 8-K filed January 5, 2024. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. (A) has filed an 8-K report on January 5, 2024, to disclose a change in its business segment reporting structure.
Effective for the quarter ending January 31, 2024, the company is moving its Cell Analysis Division from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG). This strategic reorganization aims to enhance growth opportunities within both affected divisions. This change will result in a restatement of prior period financial information to align with the new segment structure.
Investors should note that the report includes selected segment information for historical periods (fiscal quarters and years from 2021 to 2023) reflecting this updated organization, which will be incorporated into future financial statements. The information provided is furnished and not deemed filed under Section 18 of the Securities Exchange Act.
02—Key points
Key Highlights
- Agilent Technologies is reorganizing its business segments, moving the Cell Analysis Division.
- The Cell Analysis Division will be transferred from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG).
- This change is intended to strengthen growth opportunities for both LSAG and DGG.
- The new segment structure will be reflected in financial statements starting with the quarter ending January 31, 2024.
- Prior period financial statements will be recast to conform to the new reporting segments.
- The company is furnishing selected historical segment information (FY2021-2023) reflecting the updated structure.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The main purpose of this 8-K filing is to announce and provide details about a change in Agilent Technologies' business segment structure. Specifically, the Cell Analysis Division is being moved from one segment to another.
Which business segment is changing, and where is it moving?
The Cell Analysis Division is moving from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG).
When will this new segment structure take effect?
The new segment structure will take effect beginning with the fiscal quarter ending January 31, 2024. Financial statements from this period onwards will reflect the change, with prior periods being restated accordingly.
Will this reorganization affect the number of reportable business segments?
No, Agilent Technologies will continue to have three reportable business segments: LSAG, DGG, and Agilent CrossLab, even after this internal reorganization.
04—Continue